New hope for kids with rare swelling disorder: early access drug offered
NCT ID NCT07216378
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This program provides early access to an investigational drug called sebetralstat for children aged 2 to 11 with hereditary angioedema (HAE), a condition causing sudden, painful swelling. The drug is taken at the start of an attack to reduce symptoms. It is available to children who have previously been in a sebetralstat study or are new to the drug, if their doctor believes it may help.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
KalVista Investigative Site
AVAILABLESan Diego, California, 92123, United States
-
KalVista Investigative Site
AVAILABLEEvansville, Indiana, 47715, United States
-
KalVista Investigative Site
AVAILABLEWheaton, Maryland, 20902, United States
-
KalVista Investigative Site
AVAILABLESt Louis, Missouri, 63110, United States
-
KalVista Investigative Site
AVAILABLEKnoxville, Tennessee, 37909, United States
-
KalVista Investigative Site
AVAILABLESan Antonio, Texas, 78229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New oral option may offer relief for hereditary angioedema attacks
- Can a new injection tame hereditary swelling attacks?
- Could a simple pill shield HAE patients from Procedure-Triggered attacks?
- Teens with rare swelling disorder get new drug tested
- New drug shows promise for controlling rare swelling disorder
- New drug navenibart aims to tame hereditary swelling attacks